Takeda Pharmaceutical Company Limited
Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile3 entries
2015
Takeda agrees to settle most pioglitazone bladder-cancer claims
Takeda agreed to establish a settlement valued at approximately US$2.37 billion for claims alleging that pioglitazone was associated with bladder cancer. The company did not admit liability in the settlement.
2014
Pioglitazone bladder-cancer litigation
A federal jury awarded punitive damages in a case alleging that Takeda concealed risks associated with its diabetes medicine pioglitazone. The initial award was later reduced, and Takeda subsequently agreed to a broad settlement covering most related claims.
2001
TAP Pharmaceuticals Lupron marketing case
TAP Pharmaceuticals, the Takeda-Abbott joint venture, faced civil and criminal allegations concerning the marketing of Lupron and Medicare fraud. The case resulted in an approximately US$875 million settlement with U.S. authorities.